HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price target.
HC Wainwright & Co. Reiterates Buy on Largo, Maintains $17 Price Target
HC Wainwright & Co. analyst Heiko Ihle reiterates Largo (NASDAQ:LGO) with a Buy and maintains $17 price target.
Morgan Stanley Initiates Coverage On Nikola with Equal-Weight Rating, Announces Price Target of $3
Morgan Stanley analyst Dillon Cumming initiates coverage on Nikola (NASDAQ:NKLA) with a Equal-Weight rating and announces Price Target of $3.
Barclays Initiates Coverage On Amedisys with Equal-Weight Rating, Announces Price Target of $93
Barclays analyst Steve Valiquette initiates coverage on Amedisys (NASDAQ:AMED) with a Equal-Weight rating and announces Price Target of $93.
UBS Downgrades United Natural Foods to Neutral, Lowers Price Target to $32
UBS analyst Mark Carden downgrades United Natural Foods (NYSE:UNFI) from Buy to Neutral and lowers the price target from $48 to $32.
Keefe, Bruyette & Woods Downgrades Hercules Capital to Underperform, Lowers Price Target to $10.5
Keefe, Bruyette & Woods analyst Ryan Lynch downgrades Hercules Capital (NYSE:HTGC) from Market Perform to Underperform and lowers the price target from $14.5 to $10.5.
JP Morgan Downgrades Under Armour to Neutral, Lowers Price Target to $10
JP Morgan analyst Matthew Boss downgrades Under Armour (NYSE:UAA) from Overweight to Neutral and lowers the price target from $13 to $10.
TD Cowen Upgrades Moderna to Outperform, Raises Price Target to $180
TD Cowen analyst Tyler Van Buren upgrades Moderna (NASDAQ:MRNA) from Market Perform to Outperform and raises the price target from $150 to $180.
Citigroup Upgrades Charles Schwab to Buy, Lowers Price Target to $75
Citigroup analyst Chris Allen upgrades Charles Schwab (NYSE:SCHW) from Neutral to Buy and lowers the price target from $83 to $75.
Wells Fargo Upgrades Eli Lilly to Overweight, Raises Price Target to $375
Wells Fargo analyst Mohit Bansal upgrades Eli Lilly (NYSE:LLY) from Equal-Weight to Overweight and raises the price target from $360 to $375.